Regulating Conflicts of Interest in Medicine Through Public Disclosure: Evidence from a Physician Payments Sunshine Law

References

• Afendulis CC, Fendrick AM, Song Z, Landon BE, Safran DG, Mechanic RE, Chernew ME (2014) The impact of global budgets on pharmaceutical spending and utilization: Early experience from the alternative quality contract. Inquiry 51:1–7.Google Scholar
• American Academy of Actuaries. Prescription drug spending in the U.S. healthcare system: An actuarial perspective. 2018. Accessed February 7, 2020, https://www.actuary.org/sites/default/files/files/publications/PrescriptionDrugs.030718.pdf.Google Scholar
• Angrist J, Pischke J (2009) Mostly Harmless Econometrics (Princeton University Press, Princeton, NJ).Crossref, Google Scholar
• Armstrong K, Freiberg AA (2017) Challenges and opportunities in disclosing financial interests to patients. JAMA 317(17):1743–1744.Crossref, Google Scholar
• Barbour V, Clark J, Norton M, Simpson P, Veitch E (2012) Does conflict of interest disclosure worsen bias? PLoS Med. 9(4):e1001210.Crossref, Google Scholar
• Bartholow M. Top 200 prescription drugs of 2009. Pharmacy Times, May 11, 2010. Accessed January 26, 2020, https://www.pharmacytimes.com/publications/issue/2010/may2010/rxfocustopdrugs-0510.Google Scholar
• Berndt E, Gibbons R, Kolotilin A, Levine Taub A (2015) The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics. Journal of Health Economics 40:26–39.Google Scholar
• Bertrand M, Duflo E, Mullainathan S (2004) How much should we trust differences-in-differences estimates? Quart. J. Econom. 119(1):249–275.Crossref, Google Scholar
• Brennan T, Rotham D, Blank L, Blumenthal D, Chimonas S, Cohen J, Goldman J, et al. (2006) Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. JAMA 295(4):429–433.Google Scholar
• Brown JD (2016) Low-cost generic drug programs in the United States: Implications for payers and researchers. GaBi J. 5(1):6–7.Crossref, Google Scholar
• Brunt S (2018) Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from Medicare and the physician payment sunshine act. Health Serv. Res. 54(3):636–649.Crossref, Google Scholar
• Cain D, Loewenstein G, Moore D (2005) The dirt on coming clean: Perverse effects of disclosing conflicts of interest. J. Legal Stud. 34(1):1–25.Crossref, Google Scholar
• Cameron C, Miller D (2015) A practitioner’s guide to cluster-robust inference. J. Hum. Resour. 50(2):317–372.Crossref, Google Scholar
• Campbell E, Rao S, DesRoches C, Iezzoni L, Vogeli C, Bolcic-Jankovic D, Miralles P (2010) Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch. Internal Medicine 170(20):1820–1826.Crossref, Google Scholar
• Carey C, Lieber E, Miller S (2015) Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D. Preprint, submitted September 21, http://dx.doi.org/10.2139/ssrn.2663681.Google Scholar
• Chen D, Levonyan V, Reinhart S, Taksler G (2019) Mandatory disclosure: Theory and evidence from industry-physician relationships. Preprint, submitted February 10, http://dx.doi.org/10.2139/ssrn.2740559.Google Scholar
• Chernew ME, Mechanic RE, Landon BE, Safran DG (2011) Private-payer innovation in Massachusetts: The “alternative quality contract.” Health Aff. 30(1):51–61.Crossref, Google Scholar
• Chimonas S, Rozario N, Rothman D (2010) Show us the money: Lessons in transparency from state pharmaceutical marketing disclosure laws. Health Serv. Res. 45(1):98–114.Crossref, Google Scholar
• Chintagunta P, Goettler R, Kim M (2012) New drug diffusion when forward-looking physicians learn from patient feedback and detailing. J. Marketing Res. 49(6):807–821.Crossref, Google Scholar
• Chressanthis G, Khedkar P, Jain N, Poddar P, Seiders M (2012) Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs. J. Clin. Hypertens. 14(7):435–446.Crossref, Google Scholar
• Crawford V, Sobel J (1982) Strategic information transmission. Econometrica 50(6):1431–1451.Crossref, Google Scholar
• Davis J (2016) We analyzed 35,000 physician salaries. Here’s what we found. Doximity 2016. Accessed February 10, 2020, https://blog.doximity.com/articles/we-analyzed-35-000-physician-salaries-here-s-what-we-found.Google Scholar
• Effron D, Conway P (2015) When virtue leads to villainy: Advances in research on moral self-licensing. Curr. Opin. Psychol. 6:32–35.Crossref, Google Scholar
• Engelberg J, Parsons CA, Tefft N (2014) Financial conflicts of interest in medicine. Preprint, submitted January 27. https://dx.doi.org/10.2139/ssrn.2297094.Google Scholar
• Fischer M, Avorn J (2012) Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings. Health Aff. 31(10):2206–2212.Crossref, Google Scholar
• Foley K (2019) Big Pharma spent an additional $9.8 billion on marketing in the past 20 years. It worked. Quartz. January 9, 2019. Accessed February 7, 2020, https://qz.com/1517909/big-pharma-spent-an-additional-9-8-billion-on-marketing-in-the-past-20-years-it-worked/.Google Scholar
• Fugh-Berman A, Ahari S (2007) Following the script: How drug reps make friends and influence physicians. PLoS Med. 4(4):150.Crossref, Google Scholar
• Gagnon M-A, Lexchin J (2008) The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 5(1):1.Crossref, Google Scholar
• Greene J (2010) “For me there is no substitute”: Authenticity, uniqueness, and the lessons of Lipitor. AMA J. Ethics 12(10):818–823. Accessed January 15, 2020, https://journalofethics.ama-assn.org/article/me-there-no-substitute-authenticity-uniqueness-and-lessons-lipitor/2010-10.Crossref, Google Scholar
• Grennan M, Myers K, Swanson A, Chatterji A (2018) Physician-industry interactions: Persuasion and welfare. NBER Working Paper No. 24864, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Guo T, Sriram S, Manchanda P (2019) Let the sunshine in: The impact of industry payment disclosure on physician prescription behavior. Preprint, submitted February 25, http://dx.doi.org/10.2139/ssrn.2953399.Google Scholar
• Hampson L, Agrawal M, Joffe S, Gross C, Veter J, Emanuel E (2006) Patients’ views on financial conflicts of interest in cancer research trials. N. Engl. J. Med. 355(22):2330–2337.Crossref, Google Scholar
• Huang G, Shum M, Tan W (2019) Is advertising informative? Evidence from contraindicated drug prescriptions. Quant. Marketing Econom. 17(2):135–160.Crossref, Google Scholar
• Kamal R, Cox C, McDermott D (2019) What are the recent and forecasted trends in prescription drug spending? Peterson-KFF 2019. Accessed February 15, 2020, https://www.healthsystemtracker.org/chart-collection/recent-forecasted-trends-prescription-drug-spending/#item-the-majority-of-americans-favor-most-actions-to-address-high-prescription-drug-prices.Google Scholar
• Kesselheim A, Avorn J, Sarpatwari A (2016) The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA 316(8):858–871.Crossref, Google Scholar
• Klingler E (2017) 2017 Generic Drug Access and Savings Report. Association for Accessible Medicines. Accessed February 7, 2019, https://accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf.Google Scholar
• Larkin I, Ang D, Avorn J, Kesselheim AS (2014) Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children. Health Aff. 33(6):1014–1023.Crossref, Google Scholar
• Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, et al. (2017) Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 317(17):1785–1795.Crossref, Google Scholar
• Lenzer J (2016) Two years of sunshine: Has openness about payments reduced industry influence in healthcare? BMJ 354:i4608.Crossref, Google Scholar
• Lexchin J (1993) Interactions between physicians and the pharmaceutical industry: What does the literature say? CMAJ 149(10):1401–1407.Google Scholar
• Loewenstein G, Cain D, Sah S (2011) The limits of transparency: Pitfalls and potential of disclosing conflicts of interest. Amer. Econom. Rev. 101(3):423–428.Crossref, Google Scholar
• Lyu H, Xu T, Brotman D, Mayer-Blackwell B, Cooper M, Daniel M, Wick E, Saini V, Brownlee S, Makary M (2017) Overtreatment in the United States. PLoS One 12(9):e0181970.Crossref, Google Scholar
• Manchanda P, Chintagunta P (2004) Responsiveness of physician prescription behavior to salesforce effort: An individual level analysis. Marketing Lett. 15(2–3):129–145.Crossref, Google Scholar
• McPhee J (2010) Blue Cross Blue Shield of Massachusetts and Atrius Health sign alternative quality contract. PRWeb 2010. Accessed February 20, 2020, https://www.prweb.com/releases/2009/07/prweb2658864.htm.Google Scholar
• Mizik N, Jacobson R (2004) Are physicians ‘easy marks’? Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. 50(12):1704–1715.Link, Google Scholar
• Parker S (2017) Does disclosure induce cost-consciousness? Evidence from New Jersey hospitals. Working paper, Rutgers Business School.Google Scholar
• Pham-Kanter G, Alexander GC, Nair K (2012) Effect of physician payment disclosure laws on prescribing. Arch. Internal Medicine 172(10):819–821.Crossref, Google Scholar
• Pham-Kanter G, Mello M, Lehmann LS, Campbell E, Carpenter D (2017) Public awareness of and contact with physicians who receive industry payments: A national survey. J. Gen. Intern. Med. 32(7):767–774.Crossref, Google Scholar
• Régnier S (2013) What is the value of ‘me-too’ drugs? Health Care Manage. Sci. 16(4):300–313.Crossref, Google Scholar
• Rizzo JA (1999) Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. J. Law Econom. 42(1):89–116.Crossref, Google Scholar
• Rockoff JD (2012) Drug reps soften their sales pitches. Wall Street Journal (January 10), http://online.wsj.com/.Google Scholar
• Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM (2007) Pharmaceutical company payments to physicians: Early experiences with disclosure laws in Vermont and Minnesota. JAMA 297(11):1216–1223.Crossref, Google Scholar
• Sacks C, Lee C, Kesselheim A, Avorn J (2018) Medicare spending on brand-name combination medications vs their generic constituents. JAMA 320(7):650–656.Crossref, Google Scholar
• Sah S (2019) Conflict of interest disclosure as a reminder of professional norms: Clients first! Organ. Behav. Human Decision Processes 154:62–79.Crossref, Google Scholar
• Sah S, Loewenstein G (2014) Nothing to declare: Mandatory and voluntary disclosure leads advisors to avoid conflicts of interest. Psychol. Sci. 25(2):575–584.Crossref, Google Scholar
• Schondelmeyer S, Purvis L (2016) Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans, 2006 to 2015 (AARP Public Policy Institute), Washington DC.Google Scholar
• Sifferlin A (2014) Your doctor should reveal biases and pharma ties, says group. Time Magazine (September 18), https://time.com/3394900/whos-my-doctor/.Google Scholar
• Spector R (2005) Me-too drugs. Stanford Medicine Magazine (Summer), http://sm.stanford.edu/archive/stanmed/2005summer/drugs-metoo.html.Google Scholar
• Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI (2010) Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: A systematic review. PLoS Med. 7(10):e1000352.Crossref, Google Scholar
• Steinbrook R (2009) Controlling conflict of interest - proposals from the Institute of Medicine. N. Engl. J. Med. 360(21):2160–2163.Crossref, Google Scholar
• Stossel TP (2008) Has the hunt for conflicts of interest gone too far? Yes. BMJ 336(7642):476.Crossref, Google Scholar
• Sullivan T (2011) Massachusetts pharmaceutical and medical device manufactures code of conduct: Delays in release of data and changes to the regulations. Policy and Medicine (December 13), http://www.policymed.com/2011/12/massachusetts-pharmaceutical-and-medical-device-manufactures-code-of-conduct-delays-in-release-of-data-and-changes-to-the-r.html.Google Scholar
• Sullivan T (2012) Massachusetts passes partial repeat of the pharmaceutical and device manufactures code of conduct – aka the gift ban. Policy and Medicine (May 6, 2018; updated from 2012), https://www.policymed.com/2012/07/massachusetts-passes-partial-repeal-of-the-pharmaceutical-and-device-manufactures-code-of-conduct-ak.html.Google Scholar
• Sullivan T (2013) Physician payment sunshine: Some pharmaceutical companies reduced meal payments to healthcare providers. Policy and Medicine (April 22), http://www.policymed.com/2013/04/physician-payment-sunshine-some-pharmaceutical-companies-reduced-meal-payments-to-health-care-provid.html.Google Scholar
• Tringale KR, Hattangadi-Gluth JA, Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA (2017) Types and distribution of payments from industry to physicians in 2015. JAMA 317(17):1774–1784.Crossref, Google Scholar
• Wazana A (2000) Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283(3):373–380.Crossref, Google Scholar
• Wen L (2013a) Before the prescription, ask about your doctor’s finances. National Public Radio (December 14), https://www.npr.org/sections/health-shots/2013/12/14/250714833/before-the-prescription-ask-about-your-doctors-finances.Google Scholar
• Wen L (2013b) To the doctors: Why we need to be transparent with patients. Psychology Today (November 21), https://www.psychologytoday.com/us/blog/the-doctor-is-listening/201311/the-doctors-why-we-need-be-transparent-patients.Google Scholar
• Wen L (2014) What your physician won’t disclose. Ted Talks (November 2014), https://www.ted.com/talks/leana_wen_what_your_doctor_won_t_disclose.Google Scholar
• White J (2017) Top 5 priorities for healthcare executives right now. Healthcare Bus. Tech. Accessed February 4, 2021, https://www.healthcarebusinesstech.com/priorities-healthcare-executives/.Google Scholar